# A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

> **NCT07689201** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 24 (estimated)

## Conditions studied

- Gastrointestinal Neoplasms

## Interventions

- **DRUG:** Velzatinib

## Key facts

- **NCT ID:** NCT07689201
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-17
- **Primary completion:** 2027-11-29
- **Final completion:** 2029-08-17
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689201, "A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*